Literature DB >> 1500692

Selective intestinal decontamination in the prevention of bacterial infection in patients with acute liver failure.

J M Salmerón1, L Titó, A Rimola, A Mas, M A Navasa, J Llach, A Ginès, P Ginès, V Arroyo, J Rodés.   

Abstract

To investigate whether selective intestinal decontamination from oral administration of poorly absorbable antibiotics is effective in preventing bacterial infection in patients with acute liver failure, the incidence of nosocomial infection in 34 patients consecutively admitted to hospital between 1985-1990 and treated with either neomycin + colistin + nystatin or norfloxacin + nystatin (group I) was compared to the incidence of infection in 57 patients who did not receive oral, poorly absorbable antibiotics and who were consecutively admitted between 1972-1984 (group II). Patients from groups I and II had similar clinical and laboratory data at hospital admission. Twelve patients from group I and 33 from group II developed bacterial infection during the study period. The probability of infection was significantly different (p = 0.0083) in the two groups: 19% vs. 39% at the 3rd day of admission, 33% vs. 74% at the 7th day, and 48% vs. 78% at the 14th day, respectively. This difference was due to a different rate of infection from enterobacteria. Enterobacteria caused one infectious episode in group I and 24 in group II (p less than 0.001). The incidence of infections caused by other organisms, however, was similar in both groups (15 and 19 episodes, respectively). These results suggest that selective intestinal decontamination is useful in reducing the risk of infection from enterobacteria in patients with acute liver failure.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1500692     DOI: 10.1016/0168-8278(92)90171-k

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  13 in total

Review 1.  Hepatology.

Authors:  A N McNair; C J Tibbs; R Williams
Journal:  BMJ       Date:  1995-11-18

2.  Prophylaxis with enteral antibiotics in ventilated patients: selective decontamination or selective cross-infection?

Authors:  J C Hurley
Journal:  Antimicrob Agents Chemother       Date:  1995-04       Impact factor: 5.191

3.  Effects of antimicrobial prophylaxis and blood stream infections in patients with acute liver failure: a retrospective cohort study.

Authors:  Constantine J Karvellas; Jorge Cavazos; Holly Battenhouse; Valerie Durkalski; Jody Balko; Corron Sanders; William M Lee
Journal:  Clin Gastroenterol Hepatol       Date:  2014-03-25       Impact factor: 11.382

4.  Opportunistic infection in patients with acute liver failure.

Authors:  Makoto Arai; Tatsuo Kanda; Shin Yasui; Keiichi Fujiwara; Fumio Imazeki; Akira Watanabe; Takeyuki Sato; Shigeto Oda; Osamu Yokosuka
Journal:  Hepatol Int       Date:  2014-01-24       Impact factor: 6.047

Review 5.  Etiology and management of fulminant hepatic failure.

Authors:  Javier Vaquero; Andres T Blei
Journal:  Curr Gastroenterol Rep       Date:  2003-02

6.  Early diagnosis of bacterial and fungal infection in chronic cholestatic hepatitis B.

Authors:  Xiong-Zhi Wu; Dan Chen; Lian-San Zhao; Xiao-Hui Yu; Mei Wei; Yan Zhao; Qing Fang; Qian Xu
Journal:  World J Gastroenterol       Date:  2004-08-01       Impact factor: 5.742

Review 7.  Role of inflammation and infection in the pathogenesis of human acute liver failure: Clinical implications for monitoring and therapy.

Authors:  Mhairi C Donnelly; Peter C Hayes; Kenneth J Simpson
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

Review 8.  [Spontaneous bacterial peritonitis].

Authors:  J Zundler; J C Bode
Journal:  Med Klin (Munich)       Date:  1998-10-15

Review 9.  [Acute liver failure].

Authors:  K Rifai; M J Bahr
Journal:  Internist (Berl)       Date:  2003-05       Impact factor: 0.743

Review 10.  [Acute liver failure. Current aspects of diagnosis and therapy].

Authors:  M Bauer; M Paxian; A Kortgen
Journal:  Anaesthesist       Date:  2004-06       Impact factor: 1.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.